OCS 05
Alternative Names: ACT-01; BN-201; G-79; OCS-05Latest Information Update: 15 May 2024
At a glance
- Originator Bionure
- Developer Bionure; Oculis Pharma
- Class Anti-inflammatories; Antiglaucomas; Eye disorder therapies; Neuroprotectants; Peptides; Small molecules
- Mechanism of Action Brain derived neurotrophic factor agonists; Insulin-like growth factor I stimulants; Neuron modulators; Serum-glucocorticoid regulated kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Optic neuritis
- Preclinical Glaucoma; Neurotrophic keratopathy
- No development reported Multiple sclerosis; Neuromyelitis optica
Most Recent Events
- 08 May 2024 Oculis Pharma completes enrolment in its phase II ACUITY trial for Optic neuritis in France (IV) (NCT04762017) (EudraCT2020-003147-29)
- 18 Mar 2024 Oculis Pharma anticipates to submit IND application in USA, in 2024
- 19 Jul 2023 OCS 05 is still in preclinical development for Glaucoma in Spain (IV, Infusion) (Oculis Pharma Pippeline, July 2023)